VectivBio Holding AG Ordinary Shares

VECT

Valor de mercado US$ 1,06 bi

Sobre: VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. The product candidate is apraglutide, which is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which is developed as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome.

Funcionários: 42